DAVID N GILL
CIK 1106519 · President and CFO · last filed 2026-02-19
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$1.15M
Companies
9
Total Filings
63
Lifetime Open-Market Net
-$459.9K
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| EOLS | Director | 86,887 | $6.73 | $584.7K | -$203.1K | 13 | 2026-02-19 |
| Y-mAbs Therapeutics, Inc. (YMAB) Delisted | Director | 30,905 | $8.61 | $266.1K | -$364.6K | 10 | 2025-07-02 |
| Strongbridge Biopharma plc (SBBP) Delisted | Director | 0 | $2.00 | $0 | $17.0K | 8 | 2021-10-06 |
| SSKN | Director | 64,694 | $0.15 | $9.7K | $0 | 3 | 2019-11-26 |
| MELINTA THERAPEUTICS, INC. /NEW/ (MLNT) Delisted | Director | 6,000 | — | — | $30.4K | 3 | 2019-06-12 |
| MELINTA THERAPEUTICS, INC. /NEW/ (CEMP) Delisted | Director | 5,000 | — | — | $14.7K | 7 | 2017-01-05 |
| EndoChoice Holdings, Inc. (GI) Delisted | President and CFO | 0 | — | — | $33.2K | 5 | 2016-11-23 |
| ISOTIS INC (ISOT) Delisted | Director | — | — | — | $0 | 1 | 2007-10-30 |
| LMAT | Director | 6,005 | $91.96 | $552.2K | $12.3K | 3 | 2007-07-20 |
Recent Filings · Page 2 of 7
63 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-05-17 | EOLS | Sell (S) | −10,313 | -$137.7K | EDGAR |
| 2022-01-26 | EOLS | Grant (A) | +15,568 | $0 | EDGAR |
| 2021-10-06 | Strongbridge Biopharma plc (SBBP) Delisted | Disp (D) | −78,058 | $0 | EDGAR |
| 2021-10-05 | Strongbridge Biopharma plc (SBBP) Delisted | Tax (F) | −17,763 | -$36.6K | EDGAR |
| 2021-06-14 | Y-mAbs Therapeutics, Inc. (YMAB) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-05-18 | Strongbridge Biopharma plc (SBBP) Delisted | Grant (A) | +40,000 | $0 | EDGAR |
| 2021-05-17 | Strongbridge Biopharma plc (SBBP) Delisted | Tax (F) | −19,075 | -$44.8K | EDGAR |
| 2021-02-09 | EOLS | Grant (A) | +19,313 | $0 | EDGAR |
| 2021-01-20 | Y-mAbs Therapeutics, Inc. (YMAB) Delisted | Mixed | — | -$70.7K | EDGAR |
| 2020-11-20 | Y-mAbs Therapeutics, Inc. (YMAB) Delisted | Mixed | — | -$69.2K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.